OverviewChartNewsTraderScreen

Goldman Sachs Knock-Out CHKP/  DE000GG81A40  /

EUWAX
2024-05-30  10:12:06 AM Chg.- Bid10:42:46 AM Ask10:42:46 AM Underlying Strike price Expiration date Option type
0.670EUR - 0.840
Bid Size: 10,000		 0.910
Ask Size: 10,000		 Check Point Software... 155.0624 USD 2078-12-31 Put
GlobeNewswire 05-30 NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
GlobeNewswire 05-30 Holzer & Holzer, LLC Reminds Shareholders of June 4, 2024 Lead Plaintiff Deadline in Checkpoint Ther...
GlobeNewswire 05-30 ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Befo...
GlobeNewswire 05-30 SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
GlobeNewswire 05-30 OSE Immunotherapeutics Provides Business and Corporate Update
GlobeNewswire 05-30 Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
GlobeNewswire 05-30 BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Br...
GlobeNewswire 05-30 ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
GlobeNewswire 05-30 Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
GlobeNewswire 05-29 DEADLINE ALERT for LUNA, HRT, and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class ...
GlobeNewswire 05-29 DEADLINE ALERT for HRT, CKPT, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class ...
GlobeNewswire 05-29 UPDATE -- Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of L...
GlobeNewswire 05-29 ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
GlobeNewswire 05-29 Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch
GlobeNewswire 05-29 Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology...
GlobeNewswire 05-29 Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KI...
GlobeNewswire 05-29 Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR ...
GlobeNewswire 05-29 Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
GlobeNewswire 05-28 NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual ...
GlobeNewswire 05-28 7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with...
GlobeNewswire 05-28 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkp...
GlobeNewswire 05-28 Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Tril...
GlobeNewswire 05-28 TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
GlobeNewswire 05-27 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel...
GlobeNewswire 05-27 CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...